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Abstract
Macroglia, comprising astrocytes and oligodendroglial lineage cells, have long been regarded as uniform cell types of the 
central nervous system (CNS). Although regional morphological differences between these cell types were initially described 
after their identification a century ago, these differences were largely ignored. Recently, accumulating evidence suggests 
that macroglial cells form distinct populations throughout the CNS, based on both functional and morphological features. 
Moreover, with the use of refined techniques including single-cell and single-nucleus RNA sequencing, additional evidence 
is emerging for regional macroglial heterogeneity at the transcriptional level. In parallel, several studies revealed the existence 
of regional differences in remyelination capacity between CNS grey and white matter areas, both in experimental models for 
successful remyelination as well as in the chronic demyelinating disease multiple sclerosis (MS). In this review, we provide 
an overview of the diversity in oligodendroglial lineage cells and astrocytes from the grey and white matter, as well as their 
interplay in health and upon demyelination and successful remyelination. In addition, we discuss the implications of regional 
macroglial diversity for remyelination in light of its failure in MS. Since the etiology of MS remains unknown and only 
disease-modifying treatments altering the immune response are available for MS, the elucidation of macroglial diversity 
in grey and white matter and its putative contribution to the observed difference in remyelination efficiency between these 
regions may open therapeutic avenues aimed at enhancing endogenous remyelination in either area.
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Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease of 
the central nervous system (CNS) characterized by inflam-
mation [1], astrogliosis [2], and neurodegeneration [3–6]. 
MS can manifest in different disease courses, most com-
monly starting with relapsing–remitting MS (RRMS), which 
is characterized by inflammation-mediated exacerbations 
related to acute demyelination in the CNS and subsequent 
recovery. MS may also present in a progressive form in the 
absence of remission, either initially as in primary progres-
sive MS (PPMS), or following RRMS, called secondary pro-
gressive MS (SPMS). Neurodegeneration, caused in part by 
ultimate failure of remyelination, is an underlying cause of 
disease progression [3–6]. Treatments for MS are limited 
to disease-modifying treatments that reduce inflammation, 
while a regenerative treatment overcoming remyelination 
failure is currently unavailable. MS heterogeneity is also 
reflected in differences in pathology between different CNS 
regions, which is best studied in leukocortical lesions that 
span both grey matter (GM) and white matter (WM). For 
example, in leukocortical lesions, remyelination is more 
robust in the GM part than in its WM counterpart and dif-
ferences in cellular density and activation are observed [7, 
8]. This diversity in cellular identity and/or responses may 
underlie regional differences in remyelination, and although 
remyelination may occur in these lesions, remyelination is 
often insufficient in either area [9].
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The CNS predominantly consists of neurons, microglia 
and macroglia, the latter comprising astrocytes (ASTRs) 
and oligodendroglia, i.e., myelin-forming oligodendro-
cytes (OLGs) and OLG progenitor cells (OPCs). In the 
adult human brain, the ratio of glial cells to neurons is 
~ 1:1 or even smaller [10, 11], unlike a ~ 10:1 ratio, as pre-
viously commonly reported in the literature [12] and text-
books ([13]; reviewed in [11]). The CNS can be grossly 
divided into two regions, GM and WM. GM contains 
mainly neuronal cell bodies, dendrites and axon terminals, 
whereas axons primarily reside in WM. Thus, synapses 
are more prominent in GM areas, while WM areas have a 
higher myelin content. Also, the abundance of OLGs and 
ASTRs in the CNS is not uniform and is region depend-
ent. In most adult human brain regions, OLGs are the most 
numerous of glial cells, with a percentage ranging from 
29% in the visual cortex [11, 14], to 75% in the neocortex 
[11, 15, 16]. When comparing their abundance in GM and 
WM of the human frontal cortex, OLGs are more numer-
ous among the glial cells in the WM (69% versus 36.6% 
of glial cells) [11, 17]. ASTRs follow OLGs in numbers in 
most brain areas, such as in the frontal cortex WM (24% of 
glial cells), but not in the frontal cortex GM, where they 
outnumber OLGs (46.5% of glial cells) [11, 17]. What 
determines these homeostatic cell densities in distinct 
brain regions and what the functional relevance is of these 
differences are still open questions.
Over the past years, accumulating evidence indicates 
that macroglia from the GM and WM display regional 
plasticity and intrinsic heterogeneity, the first being 
adaptations of the same cell type to the local functional 
needs and responses to injury, and the latter being intrin-
sic transcriptional differences in cell populations [18]. 
These regional differences will have consequences for cell 
functioning upon CNS injury, such as demyelination and 
remyelination. Indeed, like observed in leukocortical MS 
lesions, in the cortex (GM area), remyelination is more 
efficient upon toxin-induced demyelination in experimen-
tal models for successful remyelination than in the cor-
pus callosum (WM area) [19, 20]. Here, we review the 
current literature on the diversity of macroglial cells, and 
discuss how this may contribute to regional differences in 
successful remyelination and upon remyelination failure. 
We will start with an introduction to macroglia, followed 
by a detailed overview on the topic of macroglial diver-
sity in the healthy CNS, focusing on GM and WM. Next, 
we discuss macroglial diversity in the context of regional 
differences in successful remyelination, and in light of 
remyelination failure and its implications for MS. Overall, 
this review recommends to take regional differences into 
account when developing and/or assessing remyelination-
based treatments for MS.
Introduction to macroglia
Oligodendroglial lineage cells
OLGs ensheath axons with myelin, which is a tight stack 
of several phospholipid bilayers that provides metabolic 
support to axons [21] and facilitates rapid saltatory con-
duction of nerve impulses [22, 23]. In addition, oligoden-
droglial lineage cells are involved in synapse modulation 
and neurotransmission in both GM and WM [24, 25]. 
Oligodendroglial lineage markers include the transcrip-
tion factors OLIG2 and SOX10. Mature OLGs develop 
from OPCs, which are PDGFRα and NG2 (also known as 
CSPG4)-expressing cells that comprise ~ 5% of the adult 
rodent CNS [26–28]. Of note, PDGFRα and NG2 are co-
expressed on > 99.5% of non-vascular cells in the rodent 
CNS [29, 30]. Upon maturation, these cells pass an imma-
ture, pre-myelinating stage that can be identified by the 
transient expression of BCAS1 and ENPP6 [31, 32]. At 
this intermediate pre-myelinating stage, the myelin lipids 
sulfatide and galactosylceramide are already present at the 
cell surface. Myelinating OLGs are recognized by their 
expression of myelin-specific proteins of which MBP and 
PLP are the major ones [33–35].
The process of developmental oligodendrogenesis 
and subsequent myelination is well studied in rodents. In 
an elegant fate mapping study, Kessaris and colleagues 
[36] showed that OPCs are derived from neural progeni-
tors called radial glia and populate the murine brain in 
three waves. At embryonic day 11.5 (E11.5), a first wave 
of OPCs emerges from the medial ganglionic eminence 
and anterior entopeduncular area. A second wave is gener-
ated from the lateral and/or caudal ganglionic eminences 
at E15. OPCs that emerge from both waves populate the 
murine cerebrum in a ventral to dorsal manner [36]. The 
third wave of OPCs occurs in the first week after birth 
and originates from the dorsal cortex. Remarkably, OPCs 
that are derived from the first wave disappear after birth 
and are virtually undetectable in adulthood [36]. Subse-
quent developmental myelination is a  highly orchestrated 
process. First, OPCs proliferate [37] and migrate towards 
naked axons [38]. There, OPCs differentiate into pre-mye-
linating OLGs and extend multiple processes that contact 
axons but do not yet myelinate. Upon withdrawal of mainly 
axon-derived inhibitory factors for OLG differentiation 
(reviewed in [39]), pre-myelinating OLGs retract their sec-
ondary and tertiary processes and myelin membranes are 
elaborated from the tips of the primary processes. These 
myelin membranes enwrap receptive axons multiple times, 
followed by the formation of compact myelin via cytoplas-
mic and exoplasmic reduction [40]. During myelin bio-
genesis, OLGs synthesize considerable amounts of myelin 
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components, such as MBP, PLP, galactosylceramide and 
cholesterol, which can take up to 100 times the weight 
of the cell [41]. In fact, OLGs have the highest oxidative 
metabolism of all cells in the CNS during active myelina-
tion [12, 42]. Additionally, levels of the anti-oxidant glu-
tathione are remarkably low in OLGs [43]. These features 
might explain why myelinating OLGs are exceptionally 
vulnerable to metabolic stress [44], possibly contributing 
to the multitude of pathologies involving demyelination.
Each OPC occupies an individual niche that is maintained 
by self-avoidance [45]. These OPCs can proliferate in the 
adult CNS of both rodents and humans [28, 45–48]. Notably, 
OPCs in the adult brain differ from developmental OPCs; 
adult OPCs are bound by the O4 antibody which recognizes 
sulfatide, have longer cell cycle times, slower migration 
rates, longer duration of maturation, and lower responsive-
ness to growth factors [49–53]. Surprisingly, murine adult 
OPCs differentially express 2361 genes compared to neona-
tal OPCs, while in adult OPCs only 37 genes are differen-
tially expressed compared to OLGs [54]. This indicates that 
based on their transcription profiles, adult OPCs look more 
like myelinating OLGs than neonatal OPCs. In line with this, 
a recent study that compared human OLGs in development 
and aging revealed that based on gene expression, a distinc-
tion can be made between OPCs from pediatric and adult 
brains [55]. More specifically, gene ontology annotations 
enriched in OPCs in the pediatric human brain are related 
to OLG differentiation, extracellular matrix (ECM) metabo-
lism, axon guidance and cholesterol transport, while gene 
ontology annotations enriched in OPCs in the adult human 
brain are related to regulation of cell projections, regulation 
of molecular transport, and superoxide metabolism [55]. In 
addition, rodent adult OPCs in the aged CNS have increased 
DNA damage and decreased metabolic function and fail to 
respond to differentiation signals both in vitro and in vivo 
[56]. This may underlie the poor remyelination observed in 
aged rodents [56].
Astrocytes
ASTRs have a plethora of functions, including providing 
trophic support to neurons, regulating synapse formation 
and pruning, maintaining the integrity of the blood–brain 
barrier (BBB) [57–60].  ASTRs also play a direct role in 
the formation of myelin membranes by supplying lipids to 
OLGs [61, 62]. During development in rodents, most ASTRs 
are formed after the generation of neurons and OPCs from 
radial glia [63–66]. Radial glia are a heterogeneous popula-
tion of cells which is formed based on a spatial and tempo-
ral patterning program in a columnar organization [63, 65, 
66]. While OPCs are derived mostly from the motor neuron 
progenitor (pMN) domain [63–66], three populations of 
ASTRs originate and migrate from the progenitor domains 
p1, p2 and p3, with p1 being the most dorsal and p3 being 
the most ventral domain [64]. In rodents, the first ASTRs 
are detected at embryonic day 16 [65]. After asymmetrical 
migration of newly formed ASTRs, the number of ASTRs 
largely increase in the brain by  local symmetrical division  
[66, 67]. The vast majority of ASTRs are formed during the 
first month after birth, when the ASTR population increases 
6- to 8-fold [66, 68], but in contrast to OPCs, postnatal (re)
distribution of ASTRs does not occur [65, 69, 70]. The final 
ASTR phenotype is thought to depend on its local cellular 
environment as well as on the region-specific functional 
demands [63, 65, 66]. Markers of immature ASTRs include 
Fabp7/Blbp and Fgfr3 [66, 71–74], and mature ASTR mark-
ers include Aldh1l1, S100B, Aldoc, Acsgb1, and Pla2 [66, 
75]. However, there is no uniform ASTR surface marker 
that labels all ASTRs, which complicates the isolation of the 
complete ASTR population from unlabeled (human) tissue. 
Astrocytogenesis is promoted by Sox9 and Nifa/b [76], with 
Sox9 being especially important for ASTR development in 
GM [77]. This suggests that Sox9 may have a possible role 
in ASTR diversification [76, 77]. ASTRs are further char-
acterized by the presence of filamentous proteins, including 
vimentin, desmin, synemin, and glial fibrillary acidic pro-
tein (GFAP) [78–81], of which GFAP is the most abundant 
[82–84]. In postnatal week 3, ASTRs are considered to be 
morphologically mature [85] and further aging of murine 
ASTRs does not induce major changes in their homeostatic 
and neurotransmission-regulating genes [75, 86]. However, 
ASTRs go into senescence [87], and aged murine ASTRs 
upregulate genes involved in synapse elimination and 
downregulate genes related to mitochondrial function and 
anti-oxidant capacity [86]. Moreover, upon aging, ASTRs 
acquire a more pro-inflammatory phenotype [86, 88]. The 
functional consequences of these age-related changes are not 
completely understood yet.
In conclusion, macroglia develop sequentially from radial 
glia during development, and obtain age-related changes 
in their phenotype and transcriptional profile. In addition, 
recent evidence demonstrates that macroglia from different 
regions appear as diverse populations throughout the CNS. 
In the following section, current knowledge on the regional 
diversity of OPCs, OLGs and ASTRs in GM and WM areas 
of healthy CNS will be outlined (summarized in Fig. 1).
Diversity of oligodendroglial lineage cells
Heterogeneity of oligodendrocyte progenitor cells 
in grey and white matter
Adult OPCs are scattered throughout the brain, but are more 
abundant in the corpus callosum (~ 120 cells/mm2 or 8% of 
cells) than in the cortex (~ 80 cells/mm2 or 3% of cells) of 
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young adult mice [30]. In 2002, a study reported that OPC 
formation in the cortex was affected more by mutations in 
PLP or its splice variant DM20, than OPC formation in the 
corpus callosum. This indicates that during development 
oligodendrogenesis is differentially regulated between GM 
and WM [89]. A distinct regulation of developmental oligo-
dendrogenesis in GM and WM is also observed upon condi-
tional deletion of Smoothened, a regulator of sonic hedgehog 
(Shh) signaling, which results in temporal deletion of OPCs. 
Subsequently, OPCs in WM (wmOPCs) fully repopulate the 
depleted area, while recovery of OPCs in GM (gmOPCs) is 
limited [90]. This implies that gmOPCs are more depend-
ent on Shh signaling for expansion. Subsequent studies in 
rodent models indicate that in vivo, wmOPCs mature more 
efficiently into myelinating OLGs than gmOPCs, which 
proliferate more slowly and produce fewer mature cells. 
However, survival of gmOPCs and wmOPCs is comparable 
[30, 48, 91–94]. Possibly as a consequence of this, OPC 
density in the adult rodent brain is higher in WM than in GM 
[16] (Fig. 1). Notably, the percentage of proliferating OPCs 
largely declines in WM after postnatal day 16, after which 
the OPC proportion that proliferates remains relatively sta-
ble. An ongoing more subtle decline in the proliferating OPC 
portion is observed in GM [52]. Ultimately, upon aging, the 
percentage of proliferative OPCs becomes similar in both 
GM and WM [52].
Fig. 1  Schematic representation of macroglial diversity in grey and 
white matter areas of the central nervous system (CNS). Protoplasmic 
astrocytes (ASTRs) reside in the grey matter (GM) and are highly 
connected via gap junctional coupling to other protoplasmic ASTRs 
via connexin (Cx)43 and Cx30. Fibrous ASTRs are mainly present in 
the white matter (WM), have limited coupling to other fibrous ASTRs 
and only express Cx43 (1, [185–187]). Oligodendrocyte progenitor 
cells (OPCs) in GM are morphologically less complex than OPCs 
that reside in WM (2, [90, 103]). Furthermore, more OPCs ( [7, 30, 
110]) and oligodendrocytes (OLGs; [11, 17]) are present in WM, but 
the turnover of both OPCs and OLGs (3, [133]) is lower in WM than 
in GM. OPCs differentiate more efficiently in WM than in GM (4, 
[94, 95, 99, 101]). OLGs express Cx32 and Cx47, which make het-
erotypic gap junctions with Cx30 and Cx43 on ASTRs, respectively, 
that are particular important for developmental myelination and OLG 
survival in WM (5, [183, 186, 189–191]. Finally, OPCs in GM dis-
play higher numbers in AMPA/kainate receptors (AMPARs/KAR)s, 
while NMDA receptors (NMDARs) are more abundant on wmOPCs 
(6, [52]). ASTRs are indicated with a yellow border and oligodendro-
glial lineage cells with a blue border
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A transplantation study by Viganò and colleagues [95] also 
hinted at regional differences between OPCs derived from 
GM and WM. This study demonstrated that wmOPCs dif-
ferentiate into OLGs equally well in both healthy GM and 
WM, whereas gmOPCs remain more immature irrespective 
of the environment. Hence, OPCs seem to carry a memory or 
intrinsic potential that is not altered by a new and different, 
healthy environment. In other words, gmOPCs and wmOPCs 
have functionally different phenotypes [95]. Indeed, OPCs 
display diversity in electrical properties [52, 96, 97], gene 
expression profiles [98–101], proliferation [51, 52, 101] and 
differentiation [94, 99, 101] rates, injury response [101–103], 
and other parameters [30, 104–106]. In vitro, rat postnatal day 
2-derived gmOPCs are morphologically less complex, have 
less transcripts of common OLG-maturation genes, proliferate 
more in response to PDGF and FGF2, and differentiate slower 
than wmOPCs [101] (Fig. 1). In contrast, murine postnatal 
day 8-derived wmOPCs proliferate more in response to PDGF 
than gmOPCs [107], indicating that regulation of regional 
OPC proliferation depends on multiple factors including 
developmental timing and the presence of mitogen(s). None-
theless, these findings indicate that wmOPCs are more mature 
than gmOPCs even after prolonged culture in vitro [94, 101]. 
That oligodendroglial lineage cells in the WM have a more 
complex phenotype in vitro is supported by an in vivo study 
describing that premyelinating OLGs in the corpus callosum 
have more processes and myelinate more axons in the devel-
oping rat brain at postnatal day 7 than premyelinating OLGs 
in the cortex [108]. Furthermore, in the rat cortex at postnatal 
day 50, NG2-positive OPCs present in a classical stellate form 
with processes radiating in all directions, while OPCs in the 
corpus callosum have an elongated morphology with multiple 
processes that follow axons. Additionally, OPCs in the rat cor-
pus callosum produce longer processes than OPCs in the cor-
tex [109]. In line with this, in the adult human brain, gmOPCs 
have a more regular network-like appearance than wmOPCs 
[110]. Other studies report differences in voltage-gated ion 
channels and spiking behavior of gmOPCs and wmOPCs [96]. 
More specifically, the density of AMPA/kainate receptors is 
higher on OPCs from the cortex, while on OPCs from the 
corpus callosum the density of NMDA receptors is higher at 
postnatal day 9 (Fig. 1). This observation may underlie the 
observed regional differences in proliferation and differentia-
tion rates. As electrical activity is known to stimulate OPC 
proliferation either by stimulating the release of PDGF from 
neurons or making OPCs more responsive to PDGF [111], 
the shorter cell cycle time of wmOPCs may be explained by 
a higher density of voltage-gated potassium channels and sub-
sequent higher peak outward current in WM [112, 113]. In 
turn, as NMDA receptors are involved in activity-dependent 
myelination [114, 115], the higher density of NMDA recep-
tors on wmOPCs may contribute to their greater differentia-
tion potential [52].
As OPC proliferation and differentiation are influenced 
by extrinsic factors, environmental cues may contribute to 
differences in OPC diversity. For example, more environ-
mental signals that inhibit OPC proliferation and arrest their 
differentiation are present in GM than in WM, although it is 
unknown where these signals originate [30, 94, 116]. When 
developing rats are exposed to cuprizone, a copper chelator 
that causes specific depletion of OLGs, via a maternal diet 
from gestational day 6 to postnatal day 21, the density of 
oligodendroglial lineage cells is widely impaired in cortical 
regions at postnatal day 21, whereas only mature OLGs are 
affected in the corpus callosum [117]. An increased expres-
sion of the anti-aging protein Klotho may protect wmOPCs 
from cuprizone toxicity [118]. Conversely, while prenatal 
PDGFRα-positive OPCs display remarkable regional het-
erogeneity at the transcriptional level in mice, the transcrip-
tional differences converge to a common region-independent 
profile upon transition to neonatal OPCs [119]. Single-cell 
RNA sequencing (scRNAseq) of murine CNS tissue from 
various brain regions from the developing and young adult 
murine brain revealed also a single OPC population inde-
pendent of region or age [53]. However, OPCs in the devel-
oping murine brain display more transcriptional signs of 
proliferation than OPCs in the more mature murine brain 
[53]. In the same study, a differentiation-committed OPC 
(COP) population was identified that is slightly more abun-
dant in the corpus callosum than in the somatosensory cor-
tex [53], and may reflect a difference in maturation state of 
the region in the developing brain. Similarly, independent 
single-nucleus RNA sequencing (snRNAseq) studies on 
post-mortem human brain tissue identified only one OPC 
population in the adult brain [120, 121]. A recent scR-
NAseq study on ex vivo isolated oligodendroglial lineage 
cells from surgical material revealed two transcriptionally 
different OPC populations; an early OPC population present 
in fetal tissue and a late OPC population that is present in 
pediatric, adolescent and adult tissue [55]. Similar to what 
is known during murine brain development, genes related 
to cell cycle regulation were upregulated in the early OPC 
population [55]. Hence, although it has been suggested that 
OPCs arising from the different waves might be functionally 
different and myelinate specific brain regions [122], in the 
developing murine CNS, PDGFRα-positive OPCs generated 
before birth converge on a transcriptional level, i.e., postna-
tal OPCs from brain and spinal cord have an almost similar 
transcriptional profile [119]. However, at postnatal day 7, 
OPCs from the murine spinal cord are more mature than 
OPCs in the brain based on the expression of late-stage dif-
ferentiation markers Mog, Mag, and Mal [119]. Also, in sup-
port of a single OPC population, are studies that demonstrate 
that OPCs derived from the three different waves initially 
present comparable electrophysiological capacities [52], but 
become regionally diverse postnatally. A similar acquired 
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permanent regional segregation of OPCs is observed in 
the spinal cord of zebrafish. In zebrafish, OPCs are more 
quiescent when OPC cell bodies are present in neuron-rich 
areas, whereas OPC differentiation is favored when OPC 
cell bodies reside in axo-dendritic areas [123]. Hence, in 
zebrafish, the microenvironment where the OPC cell body 
resides determines its behavioral subtype and differentiation 
capacity [123]. This may resemble the observed differences 
in OPC differentiation capacity in GM and WM. Altogether, 
postnatal OPCs from different regions are first transcription-
ally similar, and given their limited motility, segregate and 
acquire differences in protein expression and function via 
their local microenvironment.
Heterogeneity of oligodendrocytes in grey 
and white matter
In the rodent CNS, OPC differentiation into myelinating 
OLGs continues up to 8 months after birth [30, 48, 94]. 
This differentiation can be initiated by, and is required for, 
the learning of complex tasks [124]. In humans, OLGs 
may be produced continuously although OPC proliferation 
declines with age [125, 126]. Like in rodents, the learning of 
a complex motor task induces myelin remodeling in humans 
[127, 128]. In mice, OLGs that reside in the GM show less 
morphological plasticity. More specifically, two very recent 
in vivo imaging studies [129, 130] revealed that cortical 
OLGs hardly remodel their compacted myelin segments, 
whereas compacted myelin segments in WM are thickened 
upon increased axonal activity [131] or can be elongated 
when a neighboring myelin segment is ablated in zebrafish 
[132]. In the human WM, OLG turnover is especially low 
and most OLGs are formed in the first decade of life with 
an annual turnover of ~ 1 in 300 OLGs (0.3%) [133]. This in 
contrast to adult human GM, where the expansion phase of 
OLGs appears to be much longer, up to the fourth decade of 
life; combined with an annual turnover of 2.5% [133].
Whether diversity of OLG phenotype can be branded as 
heterogeneity of oligodendroglial lineage cells or their plas-
ticity, was recently reviewed by Foerster et al. [18]. Diversity 
of mature OLGs was first observed in the 1920s by Pio del 
Río-Hortega. Based on morphology, he described OLGs with 
small cell bodies and many fine processes that reside in both 
GM and WM, and three additional distinct subtypes that are 
restricted to WM [134, 135]. After this initial observation of 
the four morphological distinct mature OLG subpopulations, 
OLG heterogeneity was mostly ignored. Only recently more 
attention has been given to the diversity of OLGs [136]. The 
rise of sequencing technologies allows the study of transcrip-
tomics and has provided a considerable contribution to the 
knowledge of regional heterogeneity of developing OLGs 
[137]. First, Zhang et al. [32] produced a detailed compar-
ison of the transcriptome of the different cell types of the 
mouse cortex, including three oligodendroglial maturation 
stages. Zeisel et al. [138] performed quantitative single-cell 
analysis of the transcriptome on cells of the mouse primary 
somatosensory cortex and the hippocampal CA1 region [138]. 
This study demonstrates the possible existence of six OLG 
subpopulations based on gene expression that likely repre-
sent different maturation stages, of which one appears spe-
cific to the somatosensory cortex [138, 139]. scRNAseq on 
oligodendroglial cell types from various brain regions of the 
developing and young adult murine CNS categorizes 12 oli-
godendroglial lineage populations that include five different 
maturation stages, including one murine OPC stage (mOPC), 
one murine differentiation-committed (mCOP) stage, two 
murine newly-formed OLG stages (mNFOL), two murine 
myelin-forming OLG stages (mMFOL), and six murine 
mature OLG (mMOL) stages (Fig. 2a). Remarkably, of the 
six mMOL stages, mMOL1-4 are enriched in myelination 
genes and genes involved in lipid biosynthesis, while tran-
scripts of synapse genes are enriched in mMOL5 and mMOL6 
(Fig. 2a), both of which are predominantly present in the adult 
murine brain. In contrast to mOPCs, which are transcription-
ally similar between brain regions, of the six mMOL popu-
lations the mMOL5 population is relatively enriched in the 
Fig. 2  Schematic representation of transcriptionally distinct oligo-
dendroglial lineage cell subpopulations in murine and human physi-
ological and pathological conditions. a Single-cell RNA sequencing 
identified 12 oligodendroglial lineage cell subpopulations in ten dif-
ferent regions from the developing and adult murine central nervous 
system [53]. A single population of oligodendrocyte progenitor cells 
(mOPC1) differentiates into a single population of differentiation 
committed OPCs (mCOP). This is followed by two populations of 
newly-formed oligodendrocytes (mNFOL1/mNFOL2) and two popu-
lations of myelin membrane-forming oligodendrocytes (mMFOL1/
mMFOL2). Real diversification, as opposed to sequential matu-
ration stages, occurs in the last stage and is apparent as six mature 
oligodendrocyte populations (mMOL1-6). Of these, mMOL1-4 
express myelination and lipid biosynthesis genes, while mMOL5 and 
mMOL6 express synapse related genes. Upon induction of experi-
mental autoimmune encephalomyelitis (EAE), an animal model 
for inflammatory aspects of MS that mainly manifest in the spinal 
cord (spc), three additional OPC populations are observed, includ-
ing cycling OPCs (spc-mOPC cyc) and spc-mOPC2/3. Furthermore, 
three additional mMOL populations are observed; spc-mMOL1/2 
EAE, spc-mMOL3 EAE and spc-mMOL5/6 EAE [183]. Notably, all 
EAE-specific populations express IFN-, MHCI- and MHCII-related 
genes. b Single-nucleus RNA sequencing on human post-mortem tis-
sue of healthy subjects and MS patients identified one OPC popula-
tion (hOPC) followed by one COP population (hCOP) and one imma-
ture oligodendrocyte population (imhOLG), and an intermediate 
pre-myelinating, mature OLG population (hMOL6). Also in human, 
real diversification starts in the last maturation stage, with another 
five mature hMOL populations (hMOL1-5). Of the identified popula-
tions in human, imhOLG and hMOL2,3 and 5 are more abundant in 
multiple sclerosis (MS) tissue than in control tissue, while hMOL1 
and hMOL6 are less abundant in MS tissue [121]. Of note, although 
mMOL and hMOL share similarities, this is not reflected by the same 
group number [53]. IFN, interferon; MHC-I/II, major histocompat-
ibility complex class-I/II
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adult somatosensory cortex, and the corpus callosum has a 
relative enrichment in mMOL1, 4, 5 and 6 populations [53]. 
The identification of six different mMOL stages confirms het-
erogeneity of mature OLGs at the transcriptional level and 
their transcriptional profile indicates regional heterogeneity in 
mMOL function, including genes related to synaptic function 
instead of myelination in the cortex. Regional heterogeneity of 
mature OLGs may be acquired by the microenvironment upon 
differentiation-inducing cues [119], which is also previously 
described in human CNS development [140, 141].
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Similarly, using snRNAseq, six populations of mature 
OLGs in the adult human brain WM can be distinguished, 
Oligo1 to Oligo6 [121]. Mature human OLG populations 
are from here on referred to as hMOL1 to hMOL6, as some 
shared similarities with the six defined mMOL populations 
are evident, not necessarily reflected by the same group num-
ber [53]. Two major developmental end-stages of hMOLs 
are identified by pseudo-time analysis; hMOL6 develop via 
hMOL4 into an end-stage hMOL1, and hMOL3 develop 
via hMOL2 into end-stage hMOL5 [121] (Fig. 2b). Sur-
prisingly, myelination-related genes are highly expressed in 
the two intermediate populations hMOL3 and hMOL4, and 
not in the maturation endpoint populations [121] (Fig. 2b). 
This indicates that in addition to myelination, fully matured 
wmOLGs likely have other important functions not yet 
identified [53, 121] that may relate to myelin maintenance 
and/or function in synaptogenesis. Another possibility is 
that these two fully mature OLG populations may actively 
support neuronal function. OLGs provide trophic support 
to neurons [23], and OLGs that have formed myelin mem-
branes actively transport glycolysis products from the blood 
stream to the myelinated axon via monocarboxylate trans-
porters (MCT) 1 and 2 [21]. In addition, MCT1 in OLGs is 
required for neuronal survival and function [142]. Notably, 
in healthy brain tissue, hMOL6 are most abundant at the 
border between GM and WM [121]. While Jäkel et al. [121] 
solely studied WM brain tissue, in another recent snRNAseq 
study [120] GM, WM, and leukocortical MS lesions were 
analyzed and compared to tissue of healthy subjects. In this 
study, only one OPC population and OLG population were 
identified in healthy brain tissue. As this study focused on 
differences between healthy and MS brain tissue, the authors 
did not elaborate on potential differences between control 
GM and WM [120]. Hence, whether in humans a relative 
enrichment for one of the hMOLs in GM compared to WM 
or vice versa exists, remains to be determined.
Thus, in contrast to OPCs, mature OLGs not only dif-
fer in their morphology, but are also heterogeneous at the 
transcriptional level. As a consequence, the two divergent 
maturation hMOL patterns may have a different myelino-
genic potential, i.e., differences in composition, or number 
and length of myelin segments. Although the myelinogenic 
potential of the mMOL and hMOL populations has not yet 
been addressed, the myelinogenic potential of OLGs in dif-
ferent brain regions in vivo has been described, which will 
be discussed next.
Diversity in myelinogenic potential?
In vivo analysis of single cells revealed that OLGs in a given 
region display a great diversity in the number of myelin 
segments they elaborate, while the length of each myelin 
segment formed by an individual OLG also varies [143]. 
Although OLGs in the cerebral cortex form a slightly higher 
mean number of myelin segments per OLG and a seem-
ingly shorter myelin segment length compared to OLGs in 
the corpus callosum, the myelinogenic potential appears not 
to be region-specific [143]. This indicates that the number 
and length of myelin segments is likely regulated by micro-
environmental cues. In support of this, neuronal activity-
mediated regulations of intracellular  Ca2+ concentrations 
affect myelin sheath development [144]. Other factors that 
may affect the number of axons myelinated and the length 
of the myelin segments are axonal caliber and OPC com-
petition. For example, compared to OLGs in the cerebellar 
WM, OLGs in the corpus callosum of the rat myelinate more 
axons (9.6 versus 6.7 axons on average) and have shorter 
myelin segments, (79.1 µm versus 106.1 µm) [145], likely 
because axons in the corpus callosum have a smaller diam-
eter than those in the cerebellar WM [146]. In line with 
this observation, studies in rodents and cats demonstrate 
that larger axons provoke the production of longer, but 
fewer, myelin segments by OLGs [147–150]. Moreover, the 
density of OPCs also regulates the myelinogenic potential. 
The abundance of OPCs has a negative correlation with the 
number of myelin segments, a process mediated via Nogo-A 
[143]. In addition, OLGs that myelinate nanofibers in vitro 
adapt myelination patterns to the nanofiber diameter, i.e., 
the myelin sheath length increases with nanofiber diameter 
[151]. It is hypothesized that adapting myelination to axonal 
size is an evolved trait [145]. Motor output, which is critical 
for fast reactions upon threats, requires higher conduction 
speed than less critical data movement between the cerebral 
cortices. Hence, the first is signaled over thicker, and the 
latter over thinner, axons [145]. This evolutionary advantage 
might also underlie: (1) the differences in myelination-level 
of the adult CNS, i.e., the optic nerve consists of almost only 
myelinated axons [152] and the cortex and corpus callosum 
contain both myelinated and unmyelinated axons [153], and 
(2) the timing and duration of myelination as suggested by 
neuroimaging and cell age studies [154, 155]. For example, 
in humans, the volume of WM increases up to 19 years of 
age, while myelination of GM areas is not complete until the 
fourth decade of life [156]. The number of OLGs in mice 
is almost twofold higher in the corpus callosum than in the 
almost completely myelinated optic nerve, while OLG sur-
vival in these regions is comparable [48]. This is possibly 
due to a higher amount of myelination-stimulating signals 
from the higher number of naked receptive axons [48].
Not only the number of naked axons differs between GM 
and WM, also the direction of these axons. Thus, while in 
the axon bundles of WM tracts myelination is character-
ized by OLG processes that align with axons, the orientation 
of myelin segments in the GM is more omnidirectional as 
axons in the GM are not uniformly aligned [157]. On the 
other hand, the source of OLGs influences their myelination 
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pattern, i.e., cultured OLGs derived from the spinal cord 
generate larger myelin sheaths than OLGs from the cortex 
[151], pointing also to intrinsic differences in OLG matura-
tion from different regions. Differences between myelina-
tion during development and in the adult CNS have been 
observed as well. More specifically, myelinating OLGs that 
have developed in the optic nerve during adulthood have 
more and shorter myelin segments than OLGs formed dur-
ing early development [48]. Possibly, newly-produced OLGs 
in the adult brain either replace dying OLGs or incorporate 
between the pre-existing myelin segments and in this way, 
the total number of contributing OLGs increases [48]. While 
it is likely that axonal signals that determine myelin seg-
ment length and thickness are lacking or less prominently 
present in the adult than in the developing CNS, it cannot 
be excluded that reported differences between neonatal and 
adult OPCs may contribute [54, 106].
Whether myelin composition differs between different 
regions has not been thoroughly analyzed yet. It has been 
observed that human WM homogenates, i.e., that contain 
cells and myelin, are relatively enriched in lipid content 
(54.9% in WM versus 32.7% in GM), while human GM 
homogenates are more enriched in protein (55.3% in GM 
versus 39.0% in WM). Notably, fatty acids such as ethan-
olamine and serine glycerophosphatides, and lecithin are 
more abundant in GM than in WM homogenates, while 
cholesterol, sulfatide and cerebroside levels are higher in 
the WM lipid fraction [158, 159]. Whether this reflects the 
lower myelin content in GM or differences in myelin com-
position, and thus heterogeneity of GM and WM myelin per 
se, remains to be determined. In favor of the latter, myelin 
protein concentration and myelin protein activity from dis-
tinct human brain regions differ more than the regional dif-
ference in myelin content accounts for [160]. Although the 
concentration of PLP, MBP and activity of CNP is higher in 
WM homogenates than in their GM counterparts, the fold 
difference ranges between 3.3 × for CNP (frontal GM versus 
WM) and 9.6 × for MBP (frontal GM versus WM), which 
may point to a regional heterogeneity in myelin composi-
tion (Table 1). This hypothesis is supported by differences 
in the lipid percentage ratio which differs between 1.3 × 
(GM versus WM) for cholesterol and 3.7 × (GM versus 
WM) for cerebroside (Table 1). Plasticity of myelin is also 
observed during aging. The abundance of MBP decreases in 
healthy human aging [161, 162] and even more in patients 
with Alzheimer’s disease [163]. In contrast, in aged rhesus 
monkeys, MBP levels remain unchanged, whereas CNP 
levels increase [164]. How this plasticity in composition 
affects the quality of myelin is not yet known and whether 
this is different among species are interesting areas of future 
research.
Taken together, while OPCs are transcriptionally less 
diverse, mature OLGs intrinsically differ and constitute a 
heterogeneous group of locally established cells (Fig. 2). 
The diversity in OLGs may determine differences between 
myelination efficiency in GM and WM. Indeed, whereas oli-
godendroglial lineage cells continuously produce myelinat-
ing OLGs in WM, in GM, the majority of oligodendroglial 
lineage cells remain in an immature NG2-positive stage 
[94]. Whether the variety in myelin phenotype may also be 
a product of intrinsic differences in the myelin-producing 
cell, i.e., the OLG, in conjunction with axonal cues that 
orchestrate differences in myelinogenic potential, remains 
to be investigated. In addition to axonal cues, local cues of 
other cell types, such as regionally diverse ASTRs, may 
also affect the diversity of oligodendroglial lineage cells 
during development, aging or upon response to demyeli-
nating injury.
Table 1  Regional concentrations or activity of myelin proteins and lipids (adapted from [158, 159])
a Fold difference (FD) in concentration, activity, or percentage between regional grey matter (GM) and white matter (WM)












PLP (µg/mg protein) 95.8 488.8 5.1 48.2 398.2 8.3 516.8
MBP (µg/mg protein) 22.8 218.0 9.6 23.5 155.5 6.6 178.2
CNP (U/mg protein) 4.7 15.4 3.3 3.5 16.2 4.6 15.5
GMb WMb FDa
Lipid
Cholesterol (% of total dry weight) 22.0 27.5 1.3
Cerebroside (% of total dry weight) 5.4 19.8 3.7
Sulfatide (% of total dry weight) 1.7 5.4 3.2
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Astrocyte diversity
Astrocyte subtypes in grey and white matter 
of the adult brain
Originally, ASTRs are divided into two groups based on 
their morphology and this relates to region; protoplasmic 
ASTRs are present in GM (gmASTRs) and fibrous ASTRs 
mainly reside in WM (wmASTRs) [165–167] (Fig. 1). Pro-
toplasmic ASTRs are morphologically complex with a high 
number of fine processes that ensheath synapses and usually 
have one or two processes in contact with the microvas-
culature. Fibrous ASTRs are less complex and have long 
and thin processes with only a few branches, yielding a 
star-like appearance [78]. This morphological difference 
is accompanied by a more abundant presence of the inter-
mediate filament protein GFAP in wmASTRs compared to 
gmASTRs [168]. The distinct ASTR subtypes may relate to 
their distinct function in either area. For example, fibrous 
ASTRs and protoplasmic ASTRs differ in their handling 
of glutamate [169, 170]. Also, protoplasmic ASTRs are 
evenly distributed throughout the cortex and bear their own 
microdomain with hardly any overlap between neighboring 
cells [171, 172]. Even though the exact role of microdomain 
organization is not clear, its architecture suggests a promi-
nent role in coordination of synaptic activity and blood flow, 
potentially independent of neuronal metabolic activity [173]. 
In fact, each rodent protoplasmic ASTR covers between 
~ 20,000 and 120,000 synapses, whereas a human gmASTR 
can cover ~ 270,000–2 million synapses [171, 174], which 
may improve memory and learning [175]. In addition, in the 
rodent brain, capillary density and branching is 3–5 times 
higher in GM than in WM [176, 177], which is accompanied 
by a lower BBB permeability in GM than in WM [178]. 
In contrast, fibrous ASTRs seem specialized in providing 
structural support for myelinated axons, as they have numer-
ous overlapping processes combined with evenly spaced cell 
bodies [174]. Fibrous ASTRs are organized along WM tracts 
and longitudinally oriented in the plane of fiber bundles. 
Moreover, fibrous ASTRs also make contact with blood ves-
sels and with nodes of Ranvier, where they modulate myelin 
thickness and conduction velocity [174, 179].
The classification of ASTRs into protoplasmic and fibrous 
ASTRs may be a simplified representation of ASTR sub-
types. After the early discovery of ASTRs in 1913, Cajal 
divided ASTRs into different subclasses with a staining 
method using gold chloride that visualized both ASTRs and 
neurons, and classified ASTRs based on their morphology 
and contact with blood vessels [165, 180]. In 2006, an in 
depth morphological and biochemical analysis by Ems-
ley and Macklis [181] divided ASTRs into nine different 
classes based on morphology, GFAP, and S100B expres-
sion. Adding to the complexity of ASTR form and functions, 
human and primate ASTRs are 2.6-fold larger in diameter 
and 15.6-fold larger in volume compared to rodent ASTRs 
[182]. As this increase in size is valid for both fibrous and 
protoplasmic ASTRs, this may represent an evolutionary 
optimal increase relative to the increase in total brain size 
[182]. Also, human ASTRs extend tenfold more GFAP-
positive primary processes than their rodent counterparts 
[182]. Primates and humans have more subtypes of ASTRs 
than other mammals. Primates harbor two extra types of glia 
in the cortex; interlaminar ASTRs and varicose projection 
ASTRs [174]. It is hypothesized that these two ASTR sub-
types provide a network for the long-distance coordination 
of intracortical communication thresholds and play a role in 
coordinating blood flow [174].
Although many different morphological and functional 
subtypes of ASTRs are described, in murine scRNAseq and 
human snRNAseq studies on WM, only two to three groups 
of transcriptionally different ASTRs are defined [121, 138, 
183]. This is based on specific marker expression like Gfap 
and Mfge8 in mice [138], GPC5 for human gmASTRs, and 
CD44 for human wmASTRs [120]. Using reporter mice and 
a fluorescence-activated cell sorting panel of 81 cell sur-
face antigens, Lin et al. [184] described five different ASTR 
populations based on ASTRs isolated from cortex, cerebel-
lum, brainstem, olfactory bulb, thalamus, and spinal cord. 
These five populations displayed, in addition to a distinct 
surface antigen expression, also functional differences. Gene 
expression profiling revealed that although the five ASTR 
populations were functionally and morphologically different, 
three of the five populations were transcriptionally similar, 
indicating ASTR plasticity of a transcriptionally compa-
rable population. Therefore, combined with the other two 
transcriptionally distinct populations, and consistent with 
RNAseq studies, three intrinsic, transcriptionally heteroge-
neous populations were described in this study. Of these, one 
population was more abundant in the cortex [184]. Hence, 
diversity of form and function is not solely based on intrin-
sic transcriptional heterogeneity, but may also derive from 
ASTR plasticity. Finally, ASTR density also varies between 
different brain regions. In mice, the density of ASTRs is 
highest in the subventricular zone (2500 cells/mm2) and 
ASTRs in the corpus callosum are more dense than ASTRs 
in the cortex (~ 80 versus ~ 10 cells/mm2) [181], indicating 
that different local functional demands require different 
numbers of ASTRs.
Astrocyte coupling in grey and white matter
ASTRs are connected to each other by homotypic gap junc-
tion coupling via connexin 43 (Cx43), which is expressed 
in both gmASTRs and wmASTRs, and to a lower extent 
via Cx30, which is only expressed in gmASTRs [185, 186] 
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(Fig. 1). In rodents, dye injection experiments indicate that 
the coupling between ASTRs in GM and WM significantly 
differs. In the cortex, on average, 94 ASTRs are coupled 
with a span of 390 μm in diameter [187], while in the cor-
pus callosum ASTRs are coupled to few or no other ASTRs 
[187]. In contrast, a high degree of coupling between ASTRs 
is found in the optic nerve, with a coupling of 91% of the 
cells [188], indicating a large variety in coupling ability of 
wmASTRs [169]. Mature OLGs express Cx32 and Cx47, 
which make heterotypic gap junctions with Cx30 and Cx43 
on ASTRs, respectively. Although both gmOLGs and 
wmOLGs express Cx32 and Cx47, their expression is higher 
in wmOLGs [189]. The coupling of ASTRs/ASTRs as well 
as the coupling ASTRs/OLGs increases during development 
[190]. ASTR Cx43 coupling to OLGs may be involved in 
myelin maintenance and is suggested to play a role in redis-
tribution of potassium after neuronal activity. Indeed, OLG 
gap junction ablation [191–193] and/or the deletion of potas-
sium channel Kir4.1 in OLGs [192, 194, 195] causes vacu-
olation of myelin. Gap junctions between ASTRs and OLGs 
are also crucial for developmental myelination and survival 
of OLGs [193, 196, 197], particularly in WM [198]. In mice, 
a double knock-out of astrocytic Cx43 and Cx30 results in 
widespread pathology of WM tracts during development 
that persists with aging, and includes vacuolated OLGs and 
intramyelinic edema [198]. In contrast, GM pathology was 
only observed in part of the hippocampus and restricted to 
edematous ASTRs. Thus, gap junctions between ASTRs and 
OLGs seem less important for OLG survival and myelin 
maintenance in GM [198], which may be reflected in the 
lower expression of Cx32 and Cx47 in gmOLGs [189].
Taken together, based on gene expression, morphology, 
and function, a variety of ASTR phenotypes can be dis-
cerned with region as an important determinant. ASTRs are 
one of the first responders to CNS injury, and upon demy-
elination, ASTR subtypes may differ functionally and dif-
ferentially respond in GM versus WM. In turn, OPCs and 
mature OLGs from different regions may act differently in 
response to alterations in their microenvironment, includ-
ing to response-induced alterations in ASTR-derived signal-
ing factors, and their ability to remyelinate, which will be 
reviewed next.
Macroglial diversity upon central nervous 
system demyelination and remyelination 
in rodent models
Remyelination in grey and white matter
Regional differences in macroglia affect cells’ responses 
towards injury, and may therefore play an important 
role in the extent of disease pathology and recovery. For 
example, ASTR-mediated trafficking of mercury via gap 
junctions may result in uptake of mercury in gmOPCs, but 
not wmOPCs [199]. A valuable model to study regional 
diversity in macroglial responses upon demyelinating CNS 
is the dietary cuprizone model [200]. In adult mice, cupri-
zone feeding leads to reversible global demyelination in 
GM and WM of which the cortex and corpus callosum are 
most studied [200]. As spontaneous and robust remyeli-
nation is observed following withdrawal of the toxin, this 
model has provided insight in the process of remyelination. 
Upon demyelination in rodents, OPCs are transcription-
ally activated and recruited to the area of demyelination, 
where they differentiate into myelinating OLGs, a process 
orchestrated by signaling from local microglia and ASTRs 
[201]. When administered to adolescent mice, cuprizone 
induces a different de- and remyelination phenotype in GM 
and WM. More specifically, the initiation and peak of com-
plete demyelination is delayed in the cortex compared to 
the corpus callosum [19]. Several studies report that remy-
elination is more efficient in the corpus callosum than in 
the cortex upon cuprizone intoxication [202, 203]. How-
ever, limitations of the cuprizone model are that after initial 
demyelination, myelin debris clearance parallels the early 
processes of remyelination, i.e., mature OLGs appear regard-
less of whether the cuprizone diet is maintained or not [204]. 
Therefore, as demyelination is delayed in the cortex [19], 
likely also the re-expression of myelin proteins as well as 
remyelination are delayed in the cortex [19], preventing the 
comparison of regional differences in remyelination upon 
cuprizone feeding alone. However, upon co-administration 
of cuprizone and rapamycin, the remyelination process does 
not occur until treatment cessation [20]. Under these condi-
tions, when remyelination starts at the same time in GM and 
WM, remyelination proceeds faster in the cortex than in the 
corpus callosum [20]. Hence, the timing of demyelination 
and efficiency of remyelination are distinct between GM and 
WM. Notably, the differences in the time-course of de- and 
remyelination is also a heterogeneous process within GM 
itself; upon cuprizone-induced demyelination, the timing 
and speed of remyelination differs between the cingulate 
cortex and the GM of the hippocampus [203, 205]. Whether 
regional diversity of local macroglial responses may con-
tribute to more efficient remyelination in GM than in WM 
is discussed next.
Oligodendrocyte progenitor cell diversity 
and remyelination
Regional differences in remyelination efficiency in exper-
imental rodent models may be explained by the intrinsic 
differences between OPCs, which may be acquired during 
development. For instance, during the third OPC wave in the 
developing brain, the corpus callosum is mainly populated 
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by cortex-derived dorsal oligodendroglial lineage cells, and 
only 20% of the oligodendroglial lineage cells in the adult 
corpus callosum are from the ventral forebrain [122]. Upon 
toxin-induced demyelination in the corpus callosum, these 
dorsal-derived OPCs in the corpus callosum have a higher 
remyelination capacity than the ventral-derived OPCs and 
display an enhanced capacity to migrate and differentiate 
in vitro [206]. Also, upon cuprizone-induced demyelination, 
the expression of G-protein coupled receptor 17 (GPR17) 
is induced by OPCs in the corpus callosum, but not by 
OPCs in the cortex [207] (Fig. 3). In the corpus callosum, 
GPR17 is expressed by maturing oligodendroglial lineage 
cells, where it is involved in the initiation of differentiation 
[202]. Timely downregulation of GPR17 is required for ter-
minal OLG differentiation and myelination. Hence, GPR17 
may play a central role in orchestrating repair processes in 
WM, but not in GM, including remyelination [208]. Impor-
tantly, rodent adult OPCs respond to demyelinating injury 
by reverting to a less complex morphology [209, 210] and a 
more immature state at the transcriptional level [54] before 
differentiating and, ultimately, remyelinating denuded axons. 
In addition, activated adult OPCs display increased migra-
tory properties and accelerated differentiation compared to 
resting adult OPCs [54]. Moreover, activated adult OPCs 
directly regulate their recruitment to demyelinated areas by 
increasing their expression of IL1β and CCL2 [54]. Notably, 
regional differences were not taken into account and IL1β 
and CCL2 expression is only verified in oligodendroglial 
lineage cells in the corpus callosum [54]. In reverting to a 
more immature state, gmOPCs may have an advantage, as 
gmOPCs exert a less complex morphology than wmOPCs 
in vitro [95, 101], and are already less mature at the gene 
expression level [101]. Moreover, in vitro gmOPCs are less 
sensitive than wmOPCs to the detrimental effects of the 
inflammatory mediator IFNγ on proliferation, differentiation 
and morphology, and migrate more in response to ASTR-
secreted factors [101]. Also, growth factors that affect OPC 
behavior, including CNTF, BDNF, FGF2, and HGF, are 
differentially expressed upon GM and WM demyelination. 
Taking temporal expression into account, during cuprizone-
induced demyelination, the expression of these growth fac-
tors is upregulated during remyelination in the corpus cal-
losum, while they are not required for remyelination in the 
cortex (CNTF, BDNF) or are preferentially expressed during 
demyelination in the cortex (FGF2, HGF) [211]. Notably, 
CNTF and BDNF accelerate OPC maturation [212, 213] and 
FGF2 and HGF both enhance OPC proliferation and migra-
tion and prevent their differentiation [46, 214, 215]. Thus, 
remyelination efficiency depends on intrinsic differences 
between gmOPCs and wmOPCs as well as on the availabil-
ity of signaling factors, such as growth factors, to respond 
to. While differences in gmOPC and wmOPCs responses 
towards demyelination-relevant injury signals are evident, 
differences between responses of the distinct mature myeli-
nating OLG populations towards CNS injury have not been 
reported yet. As ASTRs are the cellular source of CNTF 
[216], BDNF [217], HGF [218], and FGF2 [219], ASTR 
diversity may contribute to the differences in remyelination 
efficiency in GM and WM.
Astrocyte diversity and remyelination
In addition to regional diversity of OPCs, ASTR responses 
towards injury may also vary between regions. Upon OLG 
and myelin loss, ASTRs become reactive, which in the 
cuprizone model involves ASTR proliferation, upregula-
tion of reactive ASTR markers such as GFAP and vimentin, 
and the elaboration of a dense network of processes [19, 
20, 204, 211, 220, 221]. In experimental demyelination 
models, ASTR reactivity is more prominent in the corpus 
callosum than in the cortex [19, 20, 204, 211, 220, 221], 
although ASTR reactivity has been suggested to start earlier 
in the cortex [222]. ASTR reactivity is regulated by pro-
inflammatory cytokines, Toll-like receptor (TLR)-mediated 
signaling events, and myelin debris [220, 223–226]. As the 
BBB remains virtually intact in the cuprizone model [227], 
most inflammatory mediators that induce ASTR reactivity 
are provided by microglia. In the cuprizone model, micro-
gliosis precedes loss of OLGs and is in the corpus callo-
sum already apparent when myelin still appears normal 
[222]. In contrast, in the cortex, microglia activation is less 
prominent and delayed [222]. Hence, early microglia acti-
vation precedes ASTR reactivity in the corpus callosum, 
while ASTR reactivity in the cortex is already evident when 
microglia activation peaks. This indicates that ASTR reac-
tivity upon GM and WM demyelination is heterogeneous 
as a consequence of differential inducing signal factors. Of 
note, both in the corpus callosum and cortex, transcripts of 
the chemokine CCL2 are transiently enhanced early upon 
cuprizone administration, while mRNA levels of CCL3 con-
tinuously increase [222]. However, when CCL2 and CCL3 
are both absent, both ASTR reactivity and demyelination in 
the cortex but not in the corpus callosum are reduced [228]. 
This is in line with the assumption that ASTR reactivity 
differs in GM and WM and therefore distinctly modulate 
de- and remyelination. Consistent with this, ASTR reactiv-
ity is heterogeneous, and depends on the type of injury and 
the inducing mediator(s) [226, 229]. Reactive ASTRs have 
been classified as anti-inflammatory A2-ASTRs, induced 
by myelin debris [224] and/or TLR3 agonists [225, 230] 
and characterized by S100A2 expression [224], and pro-
inflammatory A1-ASTRs induced by microglia-derived 
IL-1α, TNF and C1q and characterized by C3 expression 
[88, 224]. Mild activation of ASTRs may induce pro-repar-
ative A2-ASTRs, while the more reactive A1-ASTRs inhibit 
OPC proliferation, migration and differentiation and secrete 
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toxic factors for OLGs [224, 231–233]. Notably, transgenic 
overexpression of GFAP alters the chemokine secretory 
profile of ASTRs and protects against cuprizone-induced 
demyelination in the corpus callosum [234], indicating that 
ASTR reactivity that is correlated with an upregulation of 
GFAP may serve a protective function. The authors did not 
report on differences in GM.
Another feature of reactive ASTRs is increased depo-
sition of ECM proteins. Upon toxin-induced demyelina-
tion, ASTRs transiently deposit several ECM proteins, 
including CSPGs and fibronectin, which add to resolve 
injury and promote recovery [221, 235–239]. The com-
position of the ECM affects OPC behavior; fibronectin 
increases OPC proliferation and migration and inhibits 
OPC differentiation [236, 239–248], while CSPGs inhibit 
OPC proliferation, migration and differentiation [239, 
249–253]. Differentiation of neural stem cells into OPCs 
and finally into mature myelinating OLGs is, in addition 
to ECM composition, also dependent on the stiffness of 
the ECM [254]. A rigid matrix promotes OPC prolifera-
tion and early differentiation, while a soft matrix favors 
OLG maturation and myelination [254]. Regional dif-
ferences in stiffness have been observed; WM is more 
stiff compared to GM which is, among others, due to a 
higher abundance of myelin [255]. Notably, in the cupri-
zone model, a decreased stiffness in the corpus callosum 
is observed upon acute demyelination, while in chroni-
cally cuprizone-induced demyelinated lesions that fail to 
remyelinate an increase in ECM deposition and tissue 
stiffness is measured [235]. Therefore, enhanced deposi-
tion of ECM proteins in the corpus callosum may con-
tribute to recruitment and early differentiation of OPCs, 
but removal of these ECM proteins is required for OLG 
maturation and myelination. ECM proteins are degraded, 
among others, by metalloproteinases (MMPs), which are 
mainly expressed by microglia and ASTRs [256]. In the 
cuprizone model, ASTRs in the corpus callosum express 
both MMP3 and MMP12 during remyelination, while 
hardly or no expression of these MMPs was detected 
in ASTRs in the cortex [256]. This indicates that ECM 
remodeling by these MMPs is more relevant in WM than 
in GM during remyelination. Hence, it is tempting to sug-
gest that a regional difference in inducing stimuli and 
ECM remodeling by ASTRs during reactive gliosis [19, 
221] may add to local differences in remyelination effi-
ciency in the cortex and corpus callosum.
A potential role of pre-existing heterogeneity of 
gmASTRs and wmASTRs in myelination efficiency has 
recently gained more evidence. Both in vivo and in vitro 
studies have shown that ASTRs support (re)myelination 
by supplying lipids, including unsaturated fatty acids and 
cholesterol, to OLGs [61, 62]. Strikingly, when block-
ing lipid biosynthesis in ASTRs during development, 
hypomyelination is more evident in WM than in GM 
[61], indicating that developmental myelination in WM 
depends more on ASTR-derived lipids. In addition, pri-
mary gmASTRs export more cholesterol and are more 
supportive for in vitro myelination than wmASTRs [257]. 
Hence, while myelination in WM relies more on lipids 
supplied by ASTRs, gmASTRs actually appear better 
equipped for the supply of cholesterol. Surprisingly, inhi-
bition of committed cholesterol biosynthesis in wmAS-
TRs but not gmASTRs, increases in vitro myelination 
[257]. As cholesterol biosynthesis is intertwined with 
unsaturated fatty acid and non-sterol isoprenoid biosyn-
thesis [258–260], their upregulated synthesis upon block-
ing committed cholesterol synthesis may have obscured 
the effect of decreased cholesterol levels. In fact, an 
increase in non-sterol isoprenoid synthesis increases iso-
prenylation, which reduces the release of pro-inflamma-
tory cytokine IL1β from cells, including ASTRs [257, 
261] and likely also the release of other cytokines [262]. 
Therefore, modulating lipid biosynthesis in wmASTRs 
but not gmASTRs, alters the inflammatory microenvi-
ronment in WM, which affects wmOPC differentiation.
Taken together, in experimental models, the regional 
difference in remyelination efficiency may be explained 
by pre-existing OPC and ASTR heterogeneity as well as 
plasticity, which thus depends on the context of injury and 
local inducing stimuli. Whether macroglial diversity and 
their interactions may also play a role in remyelination 
efficiency in GM and WM MS lesions will be described 
next (summarized in Fig. 3).
Macroglial diversity and its relevance 
for multiple sclerosis
Remyelination in multiple sclerosis lesions
MS is a chronic inflammatory and progressive disease of 
the CNS characterized by the formation of demyelinated 
lesions that, upon failure of remyelination, ultimately lead 
to neurodegeneration and an increasing state of neurologi-
cal disability [263]. Substantial remyelination is reported 
to occur at any given age, even well into the 8th decade 
of life [7, 264–266]. However, remyelination efficiency is 
variable; lesions are most efficiently repaired in the early 
stages of MS, while remyelination is often limited upon 
aging and disease progression [201, 264, 265, 267]. More 
remyelinated lesions are detected in progressive MS than 
in RRMS, and the proportion of remyelination is lower in 
patients with cortical GM lesions [267]. Also, MS patients 
with a shorter disease duration have a smaller proportion 
of remyelinated lesions [267]. Possible explanations for 
the decrease in remyelination efficiency include failure of 
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OPC recruitment to the lesion, failure of OPC differen-
tiation into myelinating OLGs, and/or failure of OLGs to 
effectively remyelinate axons [9, 250, 268–271]. In 70% of 
WM MS lesions, OPCs are present but fail to remyelinate 
denuded axons [250, 268, 269]. This indicates that remy-
elination is often not limited by an insufficient amount of 
OPCs, but rather by a failure of OPC differentiation [268]. 
Recent snRNAseq studies confirmed that OPCs in MS 
lesions are indeed relatively quiescent on a transcriptional 
level [120, 121]. Experimental toxin-induced demyelina-
tion models revealed that the speed of remyelination, as 
other regenerative processes, decreases with age [9, 272]. 
OPC characteristics affected by aging may contribute to 
impaired OPC differentiation. For example, CREB sign-
aling in OPCs is impaired upon aging in a mouse model 
of prolonged WM cerebral hypoperfusion [273]. A recent 
study on OPCs obtained from whole rat brain revealed 
that aged OPCs acquire classical hallmarks of cell aging, 
including increased DNA damage, decreased metabolic 
function, and become irresponsive to pharmacological-
applied differentiation signals, such as miconazole and 
benzatropine [56]. The observation that myelination in 
the adult CNS is accompanied by more and shorter mye-
lin segments, and that the produced myelin is thinner, is 
also observed in remyelinated MS lesions [274]. This may 
imply that this is a feature of adult myelination, rather 
Fig. 3  Schematic representation of macroglial diversity and its role 
in remyelination (failure) in grey matter and white matter (multiple 
sclerosis) lesions. Oligodendrocyte progenitor cells (OPCs) are more 
abundant in grey matter (GM) multiple sclerosis (MS) lesions than 
in white matter (WM) MS lesions (1 [7, 8]). An increase of con-
nexin (Cx) 47 on OPCs is observed in normal appearing white mat-
ter (NAWM) (2 [312, 313]). Astroglial (ASTR) scar formation is 
observed in WM but not in GM MS lesions (3 [7, 289, 290]) and 
the ECM becomes more stiff in WM MS lesions (4 [235]). Over-
all, both upon toxin-induced demyelination and in MS, GM lesions 
remyelinate more robustly than WM lesions (5 [7, 8]). Upon toxin-
induced demyelination the expression of G-protein coupled receptor 
17 (GPR17) is induced on wmOPCs, and its timely downregulation is 
required for remyelination (6 [195, 200]. The small heat shock protein 
HSPB5 (CRYAB) is upregulated in WM but not in GM MS lesions (7 
[275, 276]). ASTRs are indicated with a yellow border and oligoden-
droglial lineage cells with a blue border
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than an impaired myelin phenotype in remyelination [48]. 
Remarkably, carbon dating studies on WM brain tissue 
revealed that newly-formed OLGs, i.e., generated from 
adult OPCs, were only detected in a small subgroup of 
patients that had an aggressive form of MS [155]. Intrigu-
ingly, in WM-derived shadow plaques, i.e., remyelinated 
areas [275], newly-formed OLGs were absent, indicating 
that remyelination is not performed by adult OPCs, but 
by mature pre-existing OLGs generated during develop-
ment [155]. This is in line with an electron microscopy 
study in disease models of cats and non-human primates 
that uncovered that mature OLGs are connected to myelin 
sheaths of different thickness, indicating that the myelin 
sheaths are generated during both development and remy-
elination [276]. Whether the contribution of ‘old’ pre-
existing mature OLGs to remyelination is specific to WM, 
or whether this is an adaptation, i.e., a ‘gain-of-function’ 
of mature OLGs as a consequence of the quiescent OPCs 
in pathological lesions, remains to be determined.
Differences in remyelination of grey and white 
matter multiple sclerosis lesions
Historically, MS was considered mainly a disease of the 
WM, but now it has been well recognized that also GM 
pathology is prominent. The distinct WM lesions are clas-
sified by demyelination and inflammatory activity [264, 
267], while GM lesions are categorized on basis of their 
location. WM MS lesions are characterized by a variable 
infiltration of lymphocytes and macrophages, glial scar for-
mation, and microglia activity [267, 277–280]. By contrast, 
GM MS lesions are characterized by the loss of OLGs in 
the presence of a seemingly intact BBB, axonal loss, mild 
astrogliosis, and reduced lymphocyte and macrophage infil-
tration [281–283]. Hence, as in toxin-induced demyelina-
tion models, GM and WM demyelination and remyelination 
may differ due to differences in the abundance and timing of 
inducing signaling factors. To study regional differences in 
remyelination, leukocortical lesions, i.e., lesions that span 
both GM and WM areas, are therefore of special interest, 
as these lesions are assumed to have a similar pathological 
background and age when comparing GM to WM. Simi-
lar to what is observed in the cuprizone model [19, 20], 
the GM cortical portion of leukocortical MS lesions has a 
higher remyelination capacity than the WM non-cortical part 
[7] (Fig. 3). In addition, the OLG density is 6.8 fold higher 
in the GM part than the WM part [7]. Also, the number 
of NG2-positive cells, which are mainly OPCs, is reduced 
in WM MS lesions compared to normal appearing WM 
(NAWM) (40–80/mm2 versus 140–150/mm2) [110]. The 
lower abundance of OPCs in WM MS lesions may be below 
the threshold for successful remyelination. In contrast, the 
number of OPCs is comparable between normal appearing 
GM (NAGM) and demyelinated GM MS lesions (98/mm2 
versus 110/mm2), and even higher than in control GM (63/
mm2) [7]. Furthermore, astrogliosis and the expression of 
OPC differentiation-inhibiting ECM components are higher 
in the WM part than in the GM part of leukocortical MS 
lesions. In addition, microglia are also more reactive in the 
WM part, possibly contributing to the differential effect on 
remyelination [7]. These findings are not restricted to leu-
kocortical lesions, i.e., also in non-leukocortical GM MS 
lesions remyelination is more pronounced than in WM MS 
lesions [8, 280]. Transcriptome analysis on post-mortem 
tissue of different brain regions of MS patients and healthy 
subjects identified more disease-related changes in the cor-
pus callosum than in the cortex most prominently in myeli-
nating OLGs, but also in ASTRs [284], hinting at diversity 
of OLG responses. Taken together, OLGs, but not OPCs, 
display the most intrinsic regional heterogeneity, while dif-
ferences in ASTR reactivity mostly depend on the presence 
of injury signals. These injury signals likely differ in GM 
and WM, including the amount of myelin debris, and the 
presence of reactive microglia. Which molecular differences 
underlie OLG diversity in MS lesion pathology is discussed 
next.
Oligodendroglial lineage cell diversity in white 
matter multiple sclerosis lesion pathology
Two independent snRNAseq studies on post-mortem WM 
brain tissue found significant differences in the transcrip-
tome of mature OLGs in WM MS lesions compared to WM 
tissue of healthy subjects, while OPCs were transcriptionally 
quiescent [120, 121]. More specifically, of the six identified 
mature hMOL populations in control human brain tissue, 
the fully mature hMOL1 that does not express high levels of 
myelination related genes and the more immature hMOL6 
population were less abundant in WM MS lesions, while 
imOLG, hMOL2, hMOL3 and hMOL5 were enriched in 
WM MS lesions (Fig. 2b). Thus, in WM MS lesions, hMOLs 
populations were skewed to the transcriptionally different 
fully mature hMOL5 population and/or other populations 
were depleted. In favor of the latter is that in MS lesions 
adult OPCs lack the capability [120] and/or receive inhibi-
tory signals [201, 239] to form new hMOLs, which may 
represent the reduced abundance of the pre-myelinating 
hMOL6 [121]. In addition, increased transcript levels of 
myelin genes were observed in mature wmOLGs in MS 
[121], hinting to the involvement of mature OLGs in remy-
elination. Spatial analysis of MS lesions uncovered that 
genes related to OPC differentiation were reduced at the 
border of WM lesions and that genes belonging to stress 
pathways and related to iron accumulation were increased 
at these borders [120]. Although not studied [121, 155], 
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nor extensively discussed yet [120], given that OPCs are 
more abundant in GM MS lesions [7, 110] and the selective 
appearance of stressed OLGs at WM lesion borders [120], 
it is tempting to suggest that remyelination in GM may pro-
ceed via newly-formed OLGs and remyelination in WM MS 
lesions via pre-existing OLGs.
Both snRNAseq studies on MS brain tissue revealed an 
immunocompetent phenotype in oligodendroglial lineage 
cells at all maturation stages, and include increased tran-
script and protein levels of major histocompatibility complex 
class I (MHC-I) [120] and MHC-II [183]. An immunocom-
petent phenotype of both OPCs and OLGs is also present in 
experimental autoimmune encephalomyelitis (EAE) [183], 
an animal model that resembles autoimmune inflamma-
tory aspects of MS. scRNAseq of spinal cord (spc)-derived 
oligodendroglial lineage cells at the peak of EAE identi-
fied eight mature spc-OLG populations, of which five are 
EAE-associated, including a spc-mMOL population that 
mainly comprises newly formed OLGs [183] (Fig. 2a). 
Further analysis identified an EAE-specific gene module 
containing genes that were more abundantly expressed by 
the newly formed OLG population and another module that 
comprised genes associated with the IFN response path-
way and MHC-I and MHC-II genes (Fig. 2a) [183]. Strik-
ingly, in contrast to control spinal cord tissue [53, 119, 183] 
where only one spc-mOPC population was present, three 
additional spc-mOPC populations were observed in EAE 
tissue. Of the three EAE-specific spc-mOPC populations, 
one was a cycling spc-mOPC population, whereas tran-
scripts of myelination related genes are increased in the 
other two spc-mOPC populations. This indicates that these 
EAE-associated spc-mOPCs were transferred from a quies-
cent state to an actively differentiating state [183] (Fig. 2a). 
Notably, transcriptionally different OPC populations are 
not detected in WM MS lesions [120, 121], indicating that 
in contrast to EAE, OPCs are likely not activated and trig-
gered to differentiate in MS. Alternatively, given that most 
post-mortem MS lesions are likely relatively old, and may 
have had their initial demyelinating event months to years 
in the past, it cannot be excluded that in newly-emerged MS 
lesions OPCs are more active. Surprisingly, EAE-associated 
spc-mOPCs also express MHC-II genes of which induc-
tion is mediated by IFNγ in vitro [183]. IFNγ also induces 
MHC-I expression in gmOPCs, and these MHC-I expressing 
gmOPCs present antigens to cytotoxic T cells [285]. Given 
that wmOPCs are more susceptible to IFNγ than gmOPCs 
in vitro [101], it would be interesting to investigate whether 
wmOPCs also display MHC-reactivity upon exposure to 
IFNγ. Of relevance, EAE-associated spc-mOPCs exhibit 
phagocytic activity, take up myelin debris and likely pre-
sent myelin-specific antigens [183]. Of note, bulk-RNAseq 
of OPCs revealed an upregulation of genes associated with 
the innate immune system, such as IL1β and CCL2 upon 
cuprizone-induced demyelination [54], but not an upregula-
tion of MHC-I or MHC-II genes in adult OPCs. Hence, it 
would be interesting to investigate with scRNAseq whether 
upon cuprizone-induced demyelination distinct OPC clusters 
can be identified.
In conclusion, the upregulation of immunomodulatory 
genes in oligodendroglial lineage cells suggests that these 
cells may have a more direct role in MS disease origin and 
progression, and contribute to OLG heterogeneity. Alterna-
tively, the upregulation of immunomodulatory genes in oli-
godendroglial lineage cells may represent a natural, transient 
response towards inflammation-mediated demyelination, but 
persists in MS. In addition, in EAE but not MS, OPCs are 
transcriptionally active, suggesting that transcriptional acti-
vation of OPCs in MS lesions is impaired.
Astroglial scar formation white matter multiple 
sclerosis lesions
ASTRs change their phenotype in demyelinated MS lesions 
and astrogliosis varies between GM and WM MS lesions. 
Phenotype clustering of ASTRs and myeloid cells with the 
use of mass cytometry and thirteen glia-related markers 
revealed the presence of five different types of ASTRs in MS 
lesions [286]. Two of these were present in the center of GM 
and WM lesions, one on the inner GM and WM rim and one 
on the WM outer rim, and the final subtype of ASTRs was 
present in NAWM. As the ASTR phenotypes localize to dif-
ferent zones of MS lesions, it is suggested that these pheno-
types are functionally diverse populations [286]. In line with 
the snRNAseq studies that identified only two to three ASTR 
subpopulations [120, 121, 183, 287], the five different ASTR 
populations may be a representation of functional plasticity 
of the same ASTR subtype in MS, rather than a representa-
tion of intrinsic ASTR heterogeneity. The two ASTR popu-
lations identified by snRNAseq both expressed RFX4 and 
represent protoplasmic ASTRs, in MS lesions characterized 
by a downregulation of SLC1A2, and fibrous/reactive ASTRs 
that express more GFAP, CRYAB and MT3 in MS tissue 
[120]. This indicates that astrogliosis is more apparent in 
WM MS lesions than in GM MS lesions. Indeed, the small 
heat shock protein CRYAB, also named HSPB5, supports 
the reactive ASTR response that contributes to demyelina-
tion in the cerebellum of the cuprizone model [288] and is 
upregulated in active and chronic WM MS lesions, but not 
in GM MS lesions in both brain and spinal cord [289, 290] 
(Fig. 3). A recent study that combines scRNAseq, Ribo-
tag RNA profiling, ATAGseq and ChIPseq identified an 
EAE disease-associated Gfap+ ASTR subpopulation that 
expressed higher levels of MAFG and lower levels of anti-
oxidant NRF2 target genes and that promoted inflammation 
during EAE [291]. A similar ASTR signature is found in 
WM MS lesions [291], indicating a robust machinery and 
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possibly allowing for therapeutic intervention overcoming 
ASTR-mediated inflammation and oxidative stress in MS.
Together with a dense network of ECM proteins, hyper-
trophic ASTRs form a so-called astroglial scar around 
inflammatory WM lesions but not GM lesions. This astro-
glial scar consists of new, proliferative ASTRs, which no 
longer occupy discrete microdomains and instead have over-
lapping processes that form a barrier against inflammation 
[231]. The astroglial scar in MS lesions is usually consid-
ered detrimental for remyelination [292, 293]. In contrast, 
even though reactive ASTRs do emerge in the corpus cal-
losum of the cuprizone model even beyond the demyelina-
tion period, the dense network of ASTR processes do not 
progress to form a barrier along the lesion upon prolonged 
cuprizone feeding [221]. Possibly, as a consequence of a 
distinct inflammatory profile, and locally expressed induc-
ing stimuli in GM and WM MS lesions, ASTR reactivity is 
increased in WM, a difference that is particularly evident in 
leukocortical lesions [7]. It would be interesting to investi-
gate whether the reactive astrogliosis and the formation of 
a glial scar in WM MS lesions may account for decreased 
presence and/or differentiation to the fully mature hMOL1 
as identified by the snRNAseq study [121].
The astroglial scar in WM lesions mainly consists of 
interwoven astrocytic processes [294]. The processes of the 
ASTRs in the glial scar are highly filamentous, expressing 
high levels of GFAP, vimentin, and nestin [295]. A func-
tion of a glial scar is to prevent spreading of inflamma-
tion to adjacent tissue, thus limiting further tissue damage 
(reviewed in [294]). At the edges of active and expanding 
WM MS lesions, CSPGs are produced by ASTRs [296] 
under control of regulator TRPM7 [297]. The reduced 
remyelination capacity in WM has been correlated with the 
accumulation of the CSPG versican, which is expressed by 
wmASTRs but not by gmASTRs in leukocortical lesions 
[7]. A high number of cells positive for NG2 (CSPG4) is 
found at the edge of the glial scar in (chronic) active MS 
lesions [110]. Although often used as a marker for OPCs, 
NG2-expressing cells can also become ASTRs in vivo [105], 
and in rodents also microglia initiate NG2 expression upon 
aging [298]. Other ECM proteins that impair OLG produc-
tion and remyelination include hyaluronan and fibronectin 
[7, 236, 239, 299–301]. Hyaluronan and its receptor CD44 
are significantly increased in the WM, but not in the GM 
part of leukocortical lesions [7]. Fibronectin is transiently 
expressed in toxin-induced demyelination models and aids 
OPC recruitment, while newly-formed OLGs only matu-
rate upon fibronectin clearance [221, 236, 242, 302–304]. 
However, while undetected in toxin-induced demyelina-
tion, ASTRs form remyelination-impairing fibronectin 
aggregates in WM MS lesions [236]. Aggregate forma-
tion is likely induced by insufficient fibronectin degrada-
tion [305] combined with chronic inflammation [236, 305, 
306]. Fibronectin aggregates persist in WM MS lesions, 
impairing OPC differentiation and thereby contributing to 
remyelination failure [236, 304]. Although GM MS lesions 
have not been studied in the context of fibronectin aggre-
gates yet, fibronectin is not present in GM marmoset EAE 
lesions [237]. Also, in vitro more fibronectin aggregates are 
formed by wmASTRs than by gmASTRs and may reflect 
intrinsic differences in alternative splicing of fibronec-
tin between gmASTRs and wmASTRs [306]. Alterations 
in ECM composition is reflected in tissue stiffness, which 
may contribute to the regional difference in remyelination 
efficiency in MS lesions. In favor of this hypothesis, tissue 
stiffness is transiently decreased in acute demyelinated WM 
MS lesions and experimental toxin-induced demyelination 
models [235], thus forming an environment which supports 
active myelination [254]. In contrast, chronic demyelinated 
WM MS lesions are stiffer than control tissue [235] (Fig. 3), 
thus providing a myelination-inhibiting environment [254]. 
Regional differences in stiffness dynamics have also been 
reported in the chronic EAE model for inflammation-medi-
ated demyelination [307]. Contrasting to chronic cuprizone 
and MS WM lesions, in EAE WM, an initial increase in 
stiffness is observed at EAE onset and peak phase of demy-
elination, which is followed by a decrease in stiffness in the 
chronic phase, while GM stiffness remains unaffected [307]. 
The latter may be a reflection of the absence of GM pathol-
ogy in murine EAE.
Astrocyte signaling in grey and white matter 
multiple sclerosis lesions
OPCs are absent in 30% of WM MS lesions [250, 269, 
270], indicating a failure of OPC recruitment. Semaphor-
ins are extracellular signaling guidance proteins that play 
an important role in OPC recruitment upon toxin-induced 
demyelination. Semaphorin 3F (Sema3F) acts as a chemo-
attractant and Sema3A as a chemo-repellent for OPCs [308]. 
In active WM MS lesions, Sema3A and Sema3F expression 
is increased in both reactive ASTRs and microglia [309, 
310]. Whereas Sema3F expression is abundant in active 
WM lesions with a high load of microglia/macrophage 
infiltration, Sema3A expression is predominant in lesions 
with less infiltrated microglia/macrophages [310]. Both 
semaphorins are also detected in GM MS lesions, but in 
GM their expression is strictly neuronal [310], indicating 
that semaphorins are differentially expressed by gmASTRs 
and wmASTRs. Upon toxin-induced demyelination in the 
spinal cord, lentivirally mediated overexpression of Sema3A 
in ASTRs inhibits OPC recruitment to demyelinated areas 
and thereby prevents remyelination [311]. When Sema3A 
is injected into focal toxin-induced demyelinated lesions, 
OPC differentiation is halted at the pre-myelinating stage 
[309]. These pre-myelinating OLGs contact axons but fail to 
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produce myelin sheaths. Thus, Sema3A in MS lesions may 
in addition to diminishing OPC recruitment, also halt dif-
ferentiation of OPCs in a pre-myelinating stage. Of note, in 
the WM part of leukocortical lesions, pre-myelinating OLGs 
with multiple processes that are associated with demyeli-
nated axons are present but fail to myelinate the denuded 
axons [7]. As gmASTRs do not express Sema3A, and as 
the expression of neuronal Sema3A does not a play major 
role in OPC recruitment [309], the differential expression of 
semaphorins in gmASTRs and wmASTRs may contribute 
to increased remyelination efficiency in GM lesions. This is 
consistent with the abundant presence of OPCs in GM MS 
lesions [7, 8].
Direct cell–cell contact via gap junctions between ASTRs 
and OLGs is altered in MS lesions. In both GM and WM 
MS lesions, Cx43 coupling between ASTRs is increased, 
which is also observed in NAGM, but not in NAWM [312, 
313]. Also, gap junction formation between GM-specific 
Cx30s is upregulated in ASTRs in GM MS lesions [313]. 
In contrast, in EAE, a loss of Cx43 expression in ASTRs 
is observed in the spinal cord [314]. Deletion of Cx43 or 
blocking Cx43 hemichannel activity, i.e., independent of 
gap junctional communication, positively affects remyeli-
nation by reducing local activation of ASTRs and favoring 
the clearance of myelin debris and the generation of pro-
regenerative microglia, thereby enhancing OPC maturation 
[315]. Gap junction formation with OLG Cx32 and OLG 
Cx47 is reduced in GM and WM MS lesions, with exten-
sion of the loss of Cx32 into NAGM and NAWM [313]. 
Cx47 expression is however increased in a number of OPCs 
in NAWM, although these OPCs have limited coupling to 
ASTRs [312, 313] (Fig. 3). Possibly this limited ASTR/OPC 
coupling is related to the failure of OPCs to differentiate into 
pre-myelinating OLGs [198, 313]. Similar as in healthy GM 
where gap junctions between ASTRs and OLGs seem less 
important for OLGs and myelin maintenance than in WM 
[198], it is tempting to hypothesize that remyelination in 
GM lesions may also be less affected by the loss of connexin 
expression by OLGs. Upon cuprizone-induced demyelina-
tion in the corpus callosum, Cx47 is initially upregulated 
in OLG processes, and in parallel a transient and de novo 
expression of Cx47 is observed in ASTRs [316]. Upon remy-
elination, Cx47 expression is switched back from ASTRs 
to the newly-formed OLGs [316]. Notably, ASTR signal-
ing via Cx47 coupling to OPCs increases the expression of 
sphingosine-1-phosphate receptor 3 (S1PR3), which is acti-
vated by the lipid signaling molecule sphingosine-1-phos-
phate (S1P), and thereby promotes OPC proliferation [317]. 
Thus, the increased expression of Cx47 in OPCs in NAWM 
may aid proliferation of OPCs, which is in line with the 
observed increase in OPC numbers in NAWM [312]. On 
the other hand, ASTRs express S1PR1, also a receptor for 
S1P. In acute GM lesions, S1PR1 expression is decreased on 
ASTRs, while it remains present on ASTRs in WM lesions. 
Of importance, in GM MS lesions, S1PR1 reappears on 
ASTRs when inflammation diminishes [318]. Moreover, 
the activation of S1PR1 on ASTRs promotes inflamma-
tion [319], indicating that expression of S1PR1 plays a role 
in inflammation of WM but not GM MS lesions. Notably, 
treatment with fingolimod, an inhibitor of S1PR, ameliorates 
EAE among others by inhibition of inflammatory activation 
of ASTRs and recovery of BBB function [319, 320]. Hence, 
ASTR/OPC and ASTR/OLG interactions are distinct in GM 
and WM and may contribute to regional differences in remy-
elination efficiency in GM and WM MS lesions and are of 
relevance for assessing therapeutic effects.
Concluding remarks and perspectives
After initially being described well over a century ago, mac-
roglial diversity has gained interest and momentum in the 
last few years, which is not only relevant for understand-
ing human pathology, including MS, where regional differ-
ences in remyelination efficiency are evident, but also for 
the design of therapeutic strategies. While OPCs appear 
transcriptionally relatively homogenous [53, 119–121], clear 
functional differences between gmOPCs and wmOPCs exist, 
both in vitro and in vivo [30, 51, 52, 94, 96–101, 104–106]. 
This may be attributed to regional differential aging of either 
OPC population and as a result renders gmOPCs likely bet-
ter equipped for remyelination. Transcriptional profiling 
further reveals that oligodendroglial lineage cells become 
more heterogeneous upon maturation and may specialize in 
different location-dependent functions [53, 119–121]. How-
ever, the exact function of these distinct populations is not 
completely clear. In this review, we have mostly focused on 
the effects on myelination and remyelination, and whether 
the more robust remyelination in GM than in WM [7, 8, 19, 
20, 211] is an indication of the significance of differences 
in macroglia from different brain regions for remyelination. 
However, other functions of oligodendroglial lineage cells 
in synaptic pruning and metabolic support of axons may also 
be differentially regulated between different brain regions 
and remains to be determined. Also, the significance and 
function of the gain of an immuno-oligodendroglial line-
age phenotype that is observed in MS and in EAE lesions 
[183, 285] in the context of remyelination (failure) between 
regions requires further exploration. Furthermore, in con-
trast to experimental models where remyelination is per-
formed by newly-formed OLGs, remyelination in WM MS 
lesions may be performed by pre-existing, mature OLGs 
[155]. Therefore, obtaining more insight into the function 
of the two transcriptionally distinct mature OLG populations 
that are reduced in WM MS brain tissue [121] is of interest, 
as well as whether transcriptionally different mature OLGs 
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exists in GM and GM MS lesions, which may contribute to 
regional differences in the extent of remyelination and MS 
pathology.
In contrast to mature OLGs, ASTRs appear less hetero-
geneous on a transcriptional level, i.e., in RNAseq studies, 
only two to three groups of transcriptionally different ASTRs 
were identified [121, 138, 183, 184]. However, ASTRs dis-
play high plasticity and adapt to the specific demands of the 
local cells and injury functional needs [65, 66], which may 
result in subsequent ASTR regional diversity [321, 322]. For 
example, demyelination in GM and WM induce different 
types of injury responses, with distinct local induced fac-
tors [323, 324], and as a consequence differences in ASTR 
reactivity. Hence, whether and how regional diversity and 
interplay between macroglia from the GM and WM con-
tribute to observed differences in remyelination efficiency 
and MS pathology is currently difficult to dissect. There-
fore, more research both in vitro and in vivo is required to 
determine whether gmASTR and wmASTRs respond differ-
ently to similar microenvironmental signals. For example, to 
exclude that the remyelination process is mainly dictated by 
the resident microenvironmental signals, homo- and hetero-
topic transplantation of either ASTR in demyelinated GM or 
WM may be considered. Such transplantation studies have 
been performed for gmOPCs and wmOPCs in healthy adult 
brains, clearly hinting at intrinsic regional differences of 
OPCs in their maturation capacity [95]. Transplantation of 
OPCs derived from different brain regions into demyelinated 
areas have not been reported yet, but given that gmOPCs are 
less mature and less susceptible to inflammatory cytokines, 
they may be better equipped for remyelination than wmOPCs 
[54, 101]. Co-cultures of primary OPCs and ASTRs will 
also be valuable in understanding the role of macroglial 
diversity on the interplay between OPCs and ASTRs from 
different regions and its effect on myelination. The role of 
microglia and infiltrating immune cells in regional differ-
ences in remyelination efficiency have not been thoroughly 
discussed in this review, but are likely to be important play-
ers in inducing different type of injury response in GM or 
WM [19, 324–327]. Also, the lower levels of myelin (debris) 
in GM [328] and the putative differences in myelin composi-
tion in GM compared to WM (Table 1) may contribute to 
regional differences in remyelination efficiency [158, 159].
Finally, many in vitro studies use GM-derived macroglia, 
while experimental models often focus on WM regions. The 
ignorance of macroglial diversity may lead to conflicting 
results obtained by in vitro and in vivo studies. Therefore, 
when studying the effect of potential remyelination promot-
ing therapeutics, research should take into account region-
specific outcomes. For example, modulating committed 
cholesterol synthesis is supportive for in vitro myelination 
when blocked in wmASTRs while having no effect when 
blocked in gmASTRs [257]. Although not studied yet, this 
may imply that enhancing committed cholesterol synthesis 
in ASTRs may actually be detrimental for remyelination in 
WM but not in GM. Hence, more refined approaches tak-
ing macroglial diversity into account will be beneficial for 
myelin research, and for the identification of therapeutic tar-
gets that may promote remyelination, particularly in WM 
MS lesions where remyelination is less effective.
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